Article - M&A, Innovation & New Drugs to Drive Pha
Post# of 72440
Quote:
The pharma and biotech stocks kicked off 2018 on a strong note, carrying on the momentum gained last year. Though the sector has been struggling lately, probably on broader market pressure, it is expected to rebound as the year progresses.
Innovation, mergers and acquisitions (M&As), strong results, product approvals and positive data flow should act as catalysts for pharma and biotech stocks.
https://www.zacks.com/commentary/152408/ma-in...rma-stocks